{"entity":{"id":"paper-mogamulizumab-vs-investigator-choice-atll-haematologica-2019","kind":"paper","name":"Mogamulizumab versus investigator's choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma","aka":["Phillips 2019","0761-009"],"tldr":"The randomised trial of mogamulizumab outside Japan, in which confirmed responses were seen in 11 per cent of people with relapsed adult T-cell leukaemia/lymphoma against none with chemotherapy.","summary":"A randomised phase 2 study in the United States, Europe and Latin America of mogamulizumab against the investigator's choice of chemotherapy in relapsed or refractory aggressive adult T-cell leukaemia/lymphoma of the acute, lymphoma and chronic subtypes, randomised 2:1 with stratification by subtype. The primary endpoint was overall response confirmed on a later assessment at eight weeks by blinded independent review.","asOf":"2026-11-03","links":[{"label":"Haematologica 2019","url":"https://doi.org/10.3324/haematol.2018.205096"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/30573506/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/30573506"}],"tags":["lymphoma-evidence-entities"],"related":[],"cancers":["adult-t-cell-leukaemia-lymphoma"],"sections":[],"technologies":[],"targets":["ccr4"],"drugs":["mogamulizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["mogamulizumab-atll-0761-009"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"Haematologica","year":2019,"doi":"10.3324/haematol.2018.205096","pmid":"30573506","authors":"Phillips AA, Fields PA, Hermine O, et al.","paperType":"rct","findings":["Confirmed overall response was 11 per cent (95 per cent confidence interval 4 to 23) with mogamulizumab (47 patients) and 0 per cent (0 to 14) with chemotherapy (24 patients).","Best response was 28 and 8 per cent respectively.","The hazard ratio for progression-free survival was 0.71 (0.41 to 1.21), and 0.57 (0.337 to 0.983) after a post hoc adjustment for an imbalance in performance status.","The commonest grade 3 or worse treatment-related adverse events with mogamulizumab were infusion-related reaction and thrombocytopenia, 9 per cent each."],"whatItMeans":"The evidence on mogamulizumab for the people with this disease who are treated in Europe and the Americas, mostly of Caribbean, African or Latin American origin. It shows activity, with a confirmed response rate far below the Japanese figure.","caveats":["Phase 2 with 71 patients.","The adjusted progression-free survival estimate was a post hoc analysis."],"participants":71},"route":"/key-papers/paper-mogamulizumab-vs-investigator-choice-atll-haematologica-2019/","neighbours":{"cancer":[{"id":"adult-t-cell-leukaemia-lymphoma","kind":"cancer","name":"Adult T-cell leukaemia/lymphoma","route":"/cancers/adult-t-cell-leukaemia-lymphoma/"}],"target":[{"id":"ccr4","kind":"target","name":"CCR4","route":"/targets/ccr4/"}],"drug":[{"id":"mogamulizumab","kind":"drug","name":"Mogamulizumab","route":"/drugs/mogamulizumab/"}],"trial":[{"id":"mogamulizumab-atll-0761-009","kind":"trial","name":"Study 0761-009: mogamulizumab against investigator's choice in relapsed adult T-cell leukaemia/lymphoma","route":"/trials/mogamulizumab-atll-0761-009/"}]}}